M
Maribel Rodriguez-Torres
Researcher at San Juan Bautista School of Medicine
Publications - 138
Citations - 13678
Maribel Rodriguez-Torres is an academic researcher from San Juan Bautista School of Medicine. The author has contributed to research in topics: Ribavirin & Hepatitis C. The author has an hindex of 44, co-authored 137 publications receiving 13171 citations. Previous affiliations of Maribel Rodriguez-Torres include Consejo Nacional de Ciencia y Tecnología & Pontifical Catholic University of Puerto Rico.
Papers
More filters
Journal ArticleDOI
1189 gs-9669, a novel ns5b non-nucleotide site ii inhibitor, demonstrates potent antiviral activity, favorable safety profile and potential for once-daily dosing
E.J. Lawitz,L. Hazan,D. Gruener,H. Hack,M. Backonja,J. Hill,P. German,Hadas Dvory-Sobol,A. Jain,Sarah Arterburn,W.J. Watkins,S. Rossi,John G. McHutchison,Maribel Rodriguez-Torres +13 more
TL;DR: No treatment-related severe adverse events, discontinuations or other safety signals were noted during dosing or the 14 day follow-up period, and the greatest antiviral activity was observed in cohorts administering 450mg and 900mg doses BID.
Journal Article
Imo-2125, a tlr9 agonist, induces immune responses which correlate with reductions in viral load in null responder hcv patients
Maribel Rodriguez-Torres,Reem Ghalib,Stuart C. Gordon,Eric Lawitz,Keyur Patel,Ronald Pruitt,Aasim Sheikh,Robert D. Arbeit,Alice Bexon,Ekambar R. Kandimalla,Melissa Precopio,Timothy J. Sullivan,Andrew J. Muir,John G. McHutchison +13 more
TL;DR: IMO-2125, a TLR9 AGonist, developsUNE RESPONSes which relate with reduction in viral load in NULL RESPONDER HCV.
Journal ArticleDOI
32 a phase 1, multi-center, randomized, placebo-controlled, dose-escalation study of imo-2125, a tlr9 agonist, in hepatitis c-nonresponders
Andrew J. Muir,Reem Ghalib,Eric Lawitz,Kushang V. Patel,Maribel Rodriguez-Torres,Aasim Sheikh,S. Sapp,R. Taylor,A. Bexon,T. Sullivan,A. Dovholuk,J.G. Mc Hutchison +11 more
Journal ArticleDOI
P1222 a phase ii study of samatasvir (idx719) in combination with simeprevir and ribavirin in treatment-naïve hcv-infected subjects with genotypes 1b and 4 (helix-1 study)
E. Lawitz,Maribel Rodriguez-Torres,T. Nguyen,Aasim Sheikh,H. Tobias,Joseph S. Galati,J. Hill,Anna S.F. Lok,David R. Nelson,G. Dubuc Patrick,Jie Chen,D. Frank,X.-J. Zhou,Z. Sullivan-Bolyai,Douglas L. Mayers +14 more
TL;DR: CC genotype for IL-28B gene has better response to treatment and may have a protective role against HCV infection as it detected significantly in non infected family members of HCV patients.
Journal ArticleDOI
A double-blind, randomized, placebo-controlled study to assess the safety, antiviral activity and pharmacokinetics of GSK2336805 when given as monotherapy and in combination with peginterferon alfa-2a and ribavirin in hepatitis C virus genotype 1-infected treatment-naive subjects.
Stephen D. Gardner,Amy Cutrell,Cindy Elko-Simms,Kimberly K. Adkison,Robert Hamatake,Jill Walker,Maribel Rodriguez-Torres,Zhi Hong +7 more
TL;DR: This 28‐day, double‐blind, randomized, placebo‐controlled study evaluated once daily GSK2336805 60 mg alone or in combination with peginterferon alfa‐2a and ribavirin in treatment‐naive genotype 1 CHC subjects.